NASDAQ:COGT 10 November 2025

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences shares rose about 8% on Wednesday, lifting the biotech’s stock toward recent highs as investors focused on a near-term U.S. regulatory checkpoint for its lead drug candidate, bezuclastinib. The stock was up at $38.17, after trading between $35.17 and $38.34.

14 January 2026

NASDAQ:COGT·Stock Market

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Shares of Cogent Biosciences slid on Wednesday, paring losses from earlier in the session, after the biotech disclosed a key regulatory filing while investors digested a cluster of insider stock sales. The stock was down 2.5% at $36.19, after touching a low of $34.33.

31 December 2025

Biotechnology·NASDAQ:COGT·Stock Market

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance

30 December 2025

NASDAQ:COGT·Pharmaceuticals·Stock Market

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor, sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival of 16.5 months vs. 9.2 months for sunitinib alone and a 46% objective response rate vs. 26% on sunitinib monotherapy. GlobeNewswire

10 November 2025

Biotechnology·NASDAQ:COGT·Pharmaceutical News·Stock Market

NASDAQ:COGT 10 November 2025 - 14 January 2026

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

TechStock² Updates

Credo Technology (NASDAQ:CRDO) Soars 21% as Wall Street Target Gap Narrows

Quantum Computing Inc. (NASDAQ:QUBT) Rally Stalls as U.S. Cash Markets Remain Closed

MARA Holdings (NASDAQ:MARA) retreats amid expanded AI exposure through bitcoin-secured loans

UiPath (NYSE:PATH) shares surge 18%, spotlight intensifies ahead of September earnings

S&P 500 Sets Record as US Markets Eye CPI After Strongest Week Since April

Top Stock Picks

AerCap

Constellation Energy

Cheniere Energy

Walt Disney

AIG

Live updates

Investment Disclaimer